1347 related articles for article (PubMed ID: 19812348)
21. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes.
Hijazi Y; Boulieu R
Drug Metab Dispos; 2002 Jul; 30(7):853-8. PubMed ID: 12065445
[TBL] [Abstract][Full Text] [Related]
22. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples.
Yamazaki H; Inoue K; Shaw PM; Checovich WJ; Guengerich FP; Shimada T
J Pharmacol Exp Ther; 1997 Nov; 283(2):434-42. PubMed ID: 9353355
[TBL] [Abstract][Full Text] [Related]
23. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI
J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160
[TBL] [Abstract][Full Text] [Related]
24. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
Gentile DM; Verhoeven CH; Shimada T; Back DJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
[TBL] [Abstract][Full Text] [Related]
25. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
[TBL] [Abstract][Full Text] [Related]
26. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.
Hagihara K; Nishiya Y; Kurihara A; Kazui M; Farid NA; Ikeda T
Drug Metab Pharmacokinet; 2008; 23(6):412-20. PubMed ID: 19122335
[TBL] [Abstract][Full Text] [Related]
27. Diazinon is activated by CYP2C19 in human liver.
Kappers WA; Edwards RJ; Murray S; Boobis AR
Toxicol Appl Pharmacol; 2001 Nov; 177(1):68-76. PubMed ID: 11708902
[TBL] [Abstract][Full Text] [Related]
28. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease.
Fisher CD; Lickteig AJ; Augustine LM; Ranger-Moore J; Jackson JP; Ferguson SS; Cherrington NJ
Drug Metab Dispos; 2009 Oct; 37(10):2087-94. PubMed ID: 19651758
[TBL] [Abstract][Full Text] [Related]
29. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.
Hyland R; Jones BC; Smith DA
Drug Metab Dispos; 2003 May; 31(5):540-7. PubMed ID: 12695341
[TBL] [Abstract][Full Text] [Related]
30. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes.
Bae SK; Cao S; Seo KA; Kim H; Kim MJ; Shon JH; Liu KH; Zhou HH; Shin JG
Drug Metab Dispos; 2008 Aug; 36(8):1679-88. PubMed ID: 18474675
[TBL] [Abstract][Full Text] [Related]
31. Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro.
Abell LM; Liu EC
J Pharmacol Exp Ther; 2011 Nov; 339(2):589-96. PubMed ID: 21828263
[TBL] [Abstract][Full Text] [Related]
32. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
Gallemann D; Wimmer E; Höfer CC; Freisleben A; Fluck M; Ladstetter B; Dolgos H
Drug Metab Dispos; 2010 Jun; 38(6):905-16. PubMed ID: 20219851
[TBL] [Abstract][Full Text] [Related]
33. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.
Feierman DE; Lasker JM
Drug Metab Dispos; 1996 Sep; 24(9):932-9. PubMed ID: 8886601
[TBL] [Abstract][Full Text] [Related]
34. Multiple cytochrome P450 isoforms are involved in the generation of a pharmacologically active thiol metabolite, whereas paraoxonase 1 and carboxylesterase 1 catalyze the formation of a thiol metabolite isomer from ticlopidine.
Kim MJ; Jeong ES; Park JS; Lee SJ; Ghim JL; Choi CS; Shin JG; Kim DH
Drug Metab Dispos; 2014 Jan; 42(1):141-52. PubMed ID: 24170778
[TBL] [Abstract][Full Text] [Related]
35. Dehydrogenation of indoline by cytochrome P450 enzymes: a novel "aromatase" process.
Sun H; Ehlhardt WJ; Kulanthaivel P; Lanza DL; Reilly CA; Yost GS
J Pharmacol Exp Ther; 2007 Aug; 322(2):843-51. PubMed ID: 17502430
[TBL] [Abstract][Full Text] [Related]
36. Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat.
Kobayashi K; Urashima K; Shimada N; Chiba K
Drug Metab Dispos; 2003 Jul; 31(7):833-6. PubMed ID: 12814958
[TBL] [Abstract][Full Text] [Related]
37. Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.
Reid JM; Kuffel MJ; Ruben SL; Morales JJ; Rinehart KL; Squillace DP; Ames MM
Clin Cancer Res; 2002 Sep; 8(9):2952-62. PubMed ID: 12231541
[TBL] [Abstract][Full Text] [Related]
38. In vitro metabolism of the calmodulin antagonist DY-9760e (3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole dihydrochloride 3.5 hydrate) by human liver microsomes: involvement of cytochromes p450 in atypical kinetics and potential drug interactions.
Tachibana S; Fujimaki Y; Yokoyama H; Okazaki O; Sudo K
Drug Metab Dispos; 2005 Nov; 33(11):1628-36. PubMed ID: 16049129
[TBL] [Abstract][Full Text] [Related]
39. Production of reactive oxygen species by microsomes enriched in specific human cytochrome P450 enzymes.
Puntarulo S; Cederbaum AI
Free Radic Biol Med; 1998 May; 24(7-8):1324-30. PubMed ID: 9626590
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]